307 related articles for article (PubMed ID: 38245115)
1. Optimising HIV pre-exposure prophylaxis and testing strategies in men who have sex with men in Australia, Thailand, and China: a modelling study and cost-effectiveness analysis.
Zhao R; Fairley CK; Cook AR; Phanuphak N; He S; Tieosapjaroen W; Chow EPF; Phillips TR; Jin Tan RK; Wei Y; Shen M; Zhuang G; Ong JJ; Zhang L
Lancet Glob Health; 2024 Feb; 12(2):e243-e256. PubMed ID: 38245115
[TBL] [Abstract][Full Text] [Related]
2. Cost-Effectiveness of Long-Acting Injectable HIV Preexposure Prophylaxis in the United States : A Cost-Effectiveness Analysis.
Neilan AM; Landovitz RJ; Le MH; Grinsztejn B; Freedberg KA; McCauley M; Wattananimitgul N; Cohen MS; Ciaranello AL; Clement ME; Reddy KP; Hyle EP; Paltiel AD; Walensky RP
Ann Intern Med; 2022 Apr; 175(4):479-489. PubMed ID: 35099992
[TBL] [Abstract][Full Text] [Related]
3. Cost and cost-effectiveness analysis of pre-exposure prophylaxis among men who have sex with men in two hospitals in Thailand.
Suraratdecha C; Stuart RM; Manopaiboon C; Green D; Lertpiriyasuwat C; Wilson DP; Pavaputanon P; Visavakum P; Monkongdee P; Khawcharoenporn T; Tharee P; Kittinunvorakoon C; Martin M
J Int AIDS Soc; 2018 Jul; 21 Suppl 5(Suppl Suppl 5):e25129. PubMed ID: 30033559
[TBL] [Abstract][Full Text] [Related]
4. Cost-effectiveness and impact of pre-exposure prophylaxis to prevent HIV among men who have sex with men in Asia: A modelling study.
Ten Brink DC; Martin-Hughes R; Minnery ME; Osborne AJ; Schmidt HA; Dalal S; Green KE; Ramaurtarsing R; Wilson DP; Kelly SL
PLoS One; 2022; 17(5):e0268240. PubMed ID: 35617169
[TBL] [Abstract][Full Text] [Related]
5. Cost-effectiveness of Cabotegravir Long-Acting for HIV Pre-exposure Prophylaxis in the United States.
Brogan AJ; Davis AE; Mellott CE; Fraysse J; Metzner AA; Oglesby AK
Pharmacoeconomics; 2024 Apr; 42(4):447-461. PubMed ID: 38267806
[TBL] [Abstract][Full Text] [Related]
6. Cost-effectiveness analysis of HIV pre-exposure prophylaxis in Japan.
Mizushima D; Nagai Y; Mezzio D; Harada K; Piao Y; Barnieh L; El Moustaid F; Cawson M; Taniguchi T
J Med Econ; 2023; 26(1):886-893. PubMed ID: 37421417
[TBL] [Abstract][Full Text] [Related]
7. Cost-effectiveness analysis of pre-exposure prophylaxis for the prevention of HIV in men who have sex with men in South Korea: a mathematical modelling study.
Choi H; Suh J; Lee W; Kim JH; Kim JH; Seong H; Ahn JY; Jeong SJ; Ku NS; Park YS; Yeom JS; Kim C; Kwon HD; Smith DM; Lee J; Choi JY
Sci Rep; 2020 Sep; 10(1):14609. PubMed ID: 32884082
[TBL] [Abstract][Full Text] [Related]
8. The cost-effectiveness of case-finding strategies for achieving hepatitis C elimination among men who have sex with men in the UK.
Macgregor L; Ward Z; Martin NK; Nicholls J; Desai M; Hickson F; Weatherburn P; Hickman M; Vickerman P
J Viral Hepat; 2021 Jun; 28(6):897-908. PubMed ID: 33759257
[TBL] [Abstract][Full Text] [Related]
9. Population-level impact of expanding PrEP coverage by offering long-acting injectable PrEP to MSM in three high-resource settings: a model comparison analysis.
Stansfield SE; Heitner J; Mitchell KM; Doyle CM; Milwid RM; Moore M; Donnell DJ; Hanscom B; Xia Y; Maheu-Giroux M; Vijver DV; Wang H; Barnabas R; Boily MC; Dimitrov DT
J Int AIDS Soc; 2023 Jul; 26 Suppl 2(Suppl 2):e26109. PubMed ID: 37439080
[TBL] [Abstract][Full Text] [Related]
10. Modelling the Epidemiological Impact and Cost-Effectiveness of PrEP for HIV Transmission in MSM in China.
Zhang L; Peng P; Wu Y; Ma X; Soe NN; Huang X; Wu H; Markowitz M; Meyers K
AIDS Behav; 2019 Feb; 23(2):523-533. PubMed ID: 29971734
[TBL] [Abstract][Full Text] [Related]
11. The cost-effectiveness of preexposure prophylaxis for HIV prevention in the United States in men who have sex with men.
Juusola JL; Brandeau ML; Owens DK; Bendavid E
Ann Intern Med; 2012 Apr; 156(8):541-50. PubMed ID: 22508731
[TBL] [Abstract][Full Text] [Related]
12. A mathematical model of biomedical interventions for HIV prevention among men who have sex with men in China.
Li J; Peng L; Gilmour S; Gu J; Ruan Y; Zou H; Hao C; Hao Y; Lau JT
BMC Infect Dis; 2018 Nov; 18(1):600. PubMed ID: 30486800
[TBL] [Abstract][Full Text] [Related]
13. The Cost-effectiveness of Human Immunodeficiency Virus (HIV) Preexposure Prophylaxis and HIV Testing Strategies in High-risk Groups in India.
Kazemian P; Costantini S; Kumarasamy N; Paltiel AD; Mayer KH; Chandhiok N; Walensky RP; Freedberg KA
Clin Infect Dis; 2020 Feb; 70(4):633-642. PubMed ID: 30921454
[TBL] [Abstract][Full Text] [Related]
14. High Interest in Long-acting Injectable Pre-exposure Prophylaxis (LAI-PrEP) for HIV Prevention Among Men Who Have Sex With Men (MSM): Result From A Nationwide Survey in Malaysia.
Paudel K; Gupta S; Gautam K; Wickersham JA; Khati A; Azwa I; Ha T; Shrestha R
J Community Health; 2023 Jun; 48(3):513-521. PubMed ID: 36732459
[TBL] [Abstract][Full Text] [Related]
15. Competing biomedical HIV prevention strategies: potential cost-effectiveness of HIV vaccines and PrEP in Seattle, WA.
Adamson B; Garrison L; Barnabas RV; Carlson JJ; Kublin J; Dimitrov D
J Int AIDS Soc; 2019 Aug; 22(8):e25373. PubMed ID: 31402591
[TBL] [Abstract][Full Text] [Related]
16. Implementation and Operational Research: A Cost-Effective, Clinically Actionable Strategy for Targeting HIV Preexposure Prophylaxis to High-Risk Men Who Have Sex With Men.
Ross EL; Cinti SK; Hutton DW
J Acquir Immune Defic Syndr; 2016 Jul; 72(3):e61-7. PubMed ID: 26977749
[TBL] [Abstract][Full Text] [Related]
17. Long-Acting Injectable Cabotegravir for HIV Preexposure Prophylaxis Among Sexual and Gender Minorities: Protocol for an Implementation Study.
Grinsztejn B; Torres TS; Hoagland B; Jalil EM; Moreira RI; O'Malley G; Shade SB; Benedetti MR; Moreira J; Simpson K; Pimenta MC; Veloso VG;
JMIR Public Health Surveill; 2023 Apr; 9():e44961. PubMed ID: 37074775
[TBL] [Abstract][Full Text] [Related]
18. Relative cost-effectiveness of long-acting injectable cabotegravir versus oral pre-exposure prophylaxis in South Africa based on the HPTN 083 and HPTN 084 trials: a modelled economic evaluation and threshold analysis.
Jamieson L; Johnson LF; Nichols BE; Delany-Moretlwe S; Hosseinipour MC; Russell C; Meyer-Rath G
Lancet HIV; 2022 Dec; 9(12):e857-e867. PubMed ID: 36356603
[TBL] [Abstract][Full Text] [Related]
19. Cost-effectiveness of oral pre-exposure prophylaxis and expanded antiretroviral therapy for preventing HIV infections in the presence of drug resistance among men who have sex with men in China: A mathematical modelling study.
Jin X; Shi L; Wang C; Qiu T; Yin Y; Shen M; Fu G; Peng Z
Lancet Reg Health West Pac; 2022 Jun; 23():100462. PubMed ID: 35542892
[TBL] [Abstract][Full Text] [Related]
20. Economic evaluation of HIV pre-exposure prophylaxis among men-who-have-sex-with-men in England in 2016.
Ong KJ; Desai S; Field N; Desai M; Nardone A; van Hoek AJ; Gill ON
Euro Surveill; 2017 Oct; 22(42):. PubMed ID: 29067902
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
